tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Bradycardia D001919 13 associated lipids
Rosacea D012393 13 associated lipids
Hematuria D006417 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Critical Illness D016638 13 associated lipids
Sarcoidosis D012507 13 associated lipids
Hypoglycemia D007003 13 associated lipids
Stomatitis D013280 14 associated lipids
Vasculitis D014657 14 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Uveitis D014605 14 associated lipids
Alopecia D000505 14 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Testicular Diseases D013733 15 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hemorrhage D006470 15 associated lipids
Neutropenia D009503 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Tremor D014202 15 associated lipids
Encephalitis D004660 15 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Choline Deficiency D002796 16 associated lipids
Cholelithiasis D002769 16 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Vascular Diseases D014652 16 associated lipids
Ulcer D014456 16 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Dermatomycoses D003881 17 associated lipids
Brain Infarction D020520 17 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Albuminuria D000419 18 associated lipids
Down Syndrome D004314 18 associated lipids
Mycoses D009181 18 associated lipids
Lymphoma D008223 18 associated lipids
Ischemia D007511 18 associated lipids
Hypothermia D007035 19 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pregnancy Complications D011248 19 associated lipids
Cough D003371 19 associated lipids
Nephritis D009393 19 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Pech T et al. Combination therapy of tacrolimus and infliximab reduces inflammatory response and dysmotility in experimental small bowel transplantation in rats. 2012 Transplantation pmid:22167049
Jain A et al. Pregnancy after liver transplantation under tacrolimus. 1997 Transplantation pmid:9293865
Kee TY et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. 2006 Transplantation pmid:16861939
Burke GW et al. Advances in pancreas transplantation. 2004 Transplantation pmid:15201688
Garrity ER and Mehra MR An update on clinical outcomes in heart and lung transplantation. 2004 Transplantation pmid:15201689
Josephson MA et al. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. 2004 Transplantation pmid:15502727
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Ciancio G et al. Randomized trial of three induction antibodies in kidney transplantation: long-term results. 2014 Transplantation pmid:24477186
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Fujita T et al. Prolonged survival of rat skin allograft by treatment with FK506 ointment. 1997 Transplantation pmid:9326422
Yoshihara S et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. 2004 Transplantation pmid:15077022
Jain AB et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. 2004 Transplantation pmid:15077034
Bierer BE et al. Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. 1990 Transplantation pmid:1694317
Eiras G et al. Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. 1990 Transplantation pmid:1694318
Gathogo E et al. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. 2016 Transplantation pmid:26413990
Yin DP et al. Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. 2001 Transplantation pmid:11391223
Bruce DS et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. 2001 Transplantation pmid:11726823
Maes BD et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. 2001 Transplantation pmid:11726827
Papadopoulos-Köhn A et al. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. 2015 Transplantation pmid:25208324
Hsiau M et al. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. 2011 Transplantation pmid:21857278
Jordan ML et al. Long-term results of pancreas transplantation under tacrolius immunosuppression. 1999 Transplantation pmid:10075592
Min DI et al. Circadian variation of tacrolimus disposition in liver allograft recipients. 1996 Transplantation pmid:8900327
Jindal RM et al. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7519799
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Kadry Z et al. Kaposi's sarcoma in liver transplant recipients on FK506. 1998 Transplantation pmid:9583882
Cherikh WS et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. 2003 Transplantation pmid:14627905
Rajesh KG et al. Mitochondrial permeability transition-pore inhibition enhances functional recovery after long-time hypothermic heart preservation. 2003 Transplantation pmid:14627909
Jugie M et al. Study of the impact of liver transplantation on the outcome of intestinal grafts in children. 2006 Transplantation pmid:16612274
Augustine JJ et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. 2006 Transplantation pmid:16612276
Laskow DA et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8878381
Xu H et al. Simultaneous bone marrow and composite tissue transplantation in rats treated with nonmyeloablative conditioning promotes tolerance. 2013 Transplantation pmid:23250336
Yang H et al. Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. 2002 Transplantation pmid:11907415
Klein IH et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. 2002 Transplantation pmid:11907418
St A Nunes FA and Lucey MR Searching for a balance when applying immunosuppression after liver transplantation. 2001 Transplantation pmid:11258425
Ringe B et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. 2001 Transplantation pmid:11258429
Steinmüller TM et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. 1994 Transplantation pmid:7524203
Singh N et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. 1994 Transplantation pmid:7524204
Sonoda T et al. Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan. 2003 Transplantation pmid:12548123
Roberti I et al. Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. 1992 Transplantation pmid:1384182
Langrehr JM et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. 1992 Transplantation pmid:1384185
Jain A et al. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. 2003 Transplantation pmid:12698091
Egashira K et al. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. 2003 Transplantation pmid:12698101
Alloway R et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. 2007 Transplantation pmid:17589351
Gaber AO et al. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. 2013 Transplantation pmid:23715050
Brito-Costa A et al. Factors Associated With Changes in Body Composition Shortly After Orthotopic Liver Transplantation: The Potential Influence of Immunosuppressive Agents. 2016 Transplantation pmid:27136260
Murase N et al. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. 1993 Transplantation pmid:7678353
Herold KC et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. 1993 Transplantation pmid:7678356
Veenhof H et al. Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. 2017 Transplantation pmid:27906832
Jin L et al. Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats. 2018 Transplantation pmid:29319618
Tourret J et al. Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. 2017 Transplantation pmid:27681266